Eduard Parellada

List of Publications by Year
in descending order

71 papers	2,654 citations	172457 29 h-index	197818 49 g-index
76 all docs	76 docs citations	76 times ranked	3115 citing authors

#	Article	IF	Citations
1	Neurofilament Light Chain Levels in Anti-NMDAR Encephalitis and Primary Psychiatric Psychosis. Neurology, 2022, 98, .	1.1	25
2	Changing trends in psychiatric emergency service admissions during the COVID-19 outbreak: Report from a worldwide epicentre. Journal of Affective Disorders, 2021, 282, 26-32.	4.1	76
3	Clinical, Neuroimmunologic, and CSF Investigations in First Episode Psychosis. Neurology, 2021, 97, e61-e75.	1.1	54
4	Glutamate and microglia activation as a driver of dendritic apoptosis: a core pathophysiological mechanism to understand schizophrenia. Translational Psychiatry, 2021, 11, 271.	4.8	46
5	M60. EARLY VERSUS DELAYED PRESCRIPTION OF CLOZAPINE AND THE COGNITIVE PERFORMANCE ON SCHIZOPHRENIA. Schizophrenia Bulletin, 2020, 46, S157-S158.	4.3	0
6	Clozapine and paliperidone palmitate antipsychotic combination in treatment-resistant schizophrenia and other psychotic disorders: A retrospective 6-month mirror-image study. European Psychiatry, 2020, 63, e71.	0.2	27
7	The positive allosteric modulator of the mGlu2 receptor JNJ-46356479 partially improves neuropathological deficits and schizophrenia-like behaviors in a postnatal ketamine mice model. Journal of Psychiatric Research, 2020, 126, 8-18.	3.1	9
8	Cognitive Reserve Assessment Scale in Health (CRASH): Its Validity and Reliability. Journal of Clinical Medicine, 2019, 8, 586.	2.4	31
9	Antipsychotic-induced weight gain and birth weight in psychosis: A fetal programming model. Journal of Psychiatric Research, 2019, 115, 29-35.	3.1	15
10	An open-treatment six-week study of the clinical effectiveness of Paliperidone Palmitate in schizophrenia: data from acute units in Spain (SHADOW study). International Journal of Psychiatry in Clinical Practice, 2018, 22, 191-199.	2.4	2
11	Real-world data on paliperidone palmitate for the treatment of schizophrenia and other psychotic disorders. International Clinical Psychopharmacology, 2018, 33, 15-33.	1.7	11
12	Metabolic syndrome or glucose challenge in first episode of psychosis?. European Psychiatry, 2017, 41, 42-46.	0.2	22
13	Microarray gene-expression study in fibroblast and lymphoblastoid cell lines from antipsychotic-naÃ¯ve first-episode schizophrenia patients. Journal of Psychiatric Research, 2017, 95, 91-101.	3.1	12
14	Antipsychotic therapy amongst Cytochrome P450 2D6 poor metabolizers in the clinical practice: A case report. Actas Espanolas De Psiquiatria, 2017, 45, 248-55.	0.1	4
15	Barriers to the Use of Long-Acting Injectable Antipsychotics in the Management of Schizophrenia. CNS Drugs, 2016, 30, 689-701.	5.9	67
16	Profile of paliperidone palmitate once-monthly long-acting injectable in the management of schizophrenia: long-term safety, efficacy, and patient acceptability – a review. Patient Preference and Adherence, 2015, 9, 695.	1.8	19
17	Network analysis of gene expression in peripheral blood identifies mTOR and NF-Î°B pathways involved in antipsychotic-induced extrapyramidal symptoms. Pharmacogenomics Journal, 2015, 15, 452-460.	2.0	18
18	Intramuscular long-acting paliperidone palmitate in acute patients with schizophrenia unsuccessfully treated with oral antipsychotics. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2015, 58, 1-7.	4.8	52

#	Article	IF	Citations
19	Plasma levels of oral risperidone during enteral nutrition in a pregnant schizophrenic patient. Therapeutic Advances in Psychopharmacology, 2015, 5, 133-137.	2.7	2
20	Apoptotic markers in cultured fibroblasts correlate with brain metabolites and regional brain volume in antipsychotic-naive first-episode schizophrenia and healthy controls. Translational Psychiatry, 2015, 5, e626-e626.	4.8	30
21	Brain Metabolism during Hallucination-Like Auditory Stimulation in Schizophrenia. PLoS ONE, 2014, 9, e84987.	2.5	25
22	A Prospective Flexible-Dose Study of Paliperidone Palmitate in Nonacute But Symptomatic Patients With Schizophrenia Previously Unsuccessfully Treated With Oral Antipsychotic Agents. Clinical Therapeutics, 2014, 36, 1372-1388.e1.	2.5	35
23	Increased susceptibility to apoptosis in cultured fibroblasts from antipsychotic-naÃ¯ve first-episode schizophrenia patients. Journal of Psychiatric Research, 2014, 48, 94-101.	3.1	45
24	Screening for substance use disorders in first-episode psychosis: Implications for readmission. Schizophrenia Research, 2013, 146, 125-131.	2.0	29
25	Effectiveness of long-acting injectable risperidone versus oral antipsychotics in the treatment of recent-onset schizophrenia. International Clinical Psychopharmacology, 2013, 28, 1.	1.7	20
26	Long-Acting Injectable Antipsychotics in First-Episode Schizophrenia. Schizophrenia Research and Treatment, 2012, 2012, 1-3.	1.5	18
27	Left amygdalar activation in deficit syndrome compared with non-deficit subjects with schizophrenia during the control task in a facial emotion recognition paradigm. Psychiatry Research - Neuroimaging, 2012, 203, 109-110.	1.8	3
28	Neurotoxic/neuroprotective activity of haloperidol, risperidone and paliperidone in neuroblastoma cells. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2012, 36, 71-77.	4.8	47
29	Prolactin concentrations in newly diagnosed, antipsychotic-naÃ¯ve patients with nonaffective psychosis. Schizophrenia Research, 2012, 134, 16-19.	2.0	74
30	Intuitive pharmacogenetics: spontaneous risperidone dosage is related to CYP2D6, CYP3A5 and ABCB1 genotypes. Pharmacogenomics Journal, 2012, 12, 255-259.	2.0	35
31	Successful treatment of catatonic syndrome in bipolar I disorder adding aripiprazole to ECT: A case report. European Journal of Psychiatry, 2012, 26, 169-173.	1.3	0
32	Searching for functional SNPs or rare variants in exonic regions of DRD3 in risperidone-treated patients. European Neuropsychopharmacology, 2011, 21, 294-299.	0.7	12
33	Testosterone in Newly Diagnosed, Antipsychotic-Naive Men With Nonaffective Psychosis. Psychosomatic Medicine, 2011, 73, 643-647.	2.0	38
34	A 4-year dopamine transporter (DAT) imaging study in neuroleptic-naive first episode schizophrenia patients. Psychiatry Research - Neuroimaging, 2011, 194, 79-84.	1.8	11
35	Differential brain glucose metabolic patterns in antipsychotic-naive first-episode schizophrenia with and without auditory verbal hallucinations. Journal of Psychiatry and Neuroscience, 2011, 36, 312-321.	2.4	29
36	Safety and efficacy of long-acting injectable risperidone in daily practice: an open-label, noninterventional, prospective study in schizophrenia and related disorders. International Clinical Psychopharmacology, 2010, 25, 149-154.	1.7	13

#	Article	IF	Citations
37	Antipsychotic Treatment in a Patient With Schizophrenia Undergoing Hemodialysis. Journal of Clinical Psychopharmacology, 2010, 30, 92-94.	1.4	4
38	18FDG PET study of amygdalar activity during facial emotion recognition in schizophrenia. European Archives of Psychiatry and Clinical Neuroscience, 2010, 260, 69-76.	3.2	29
39	Lack of association between schizophrenia and polymorphisms in dopamine metabolism and transport genes. Fundamental and Clinical Pharmacology, 2010, 24, 741-747.	1.9	11
40	Lack of association between antipsychotic-induced extrapyramidal symptoms and polymorphisms in dopamine metabolism and transport genes. Psychiatry Research, 2010, 175, 173-175.	3.3	17
41	Metabolic profile of antipsychotic-naive individuals with non-affective psychosis. British Journal of Psychiatry, 2009, 194, 434-438.	2.8	224
42	Telomere Length and Pulse Pressure in Newly Diagnosed, Antipsychotic-Naive Patients With Nonaffective Psychosis. Schizophrenia Bulletin, 2009, 35, 437-442.	4.3	92
43	A continuous emotional task activates the left amygdala in healthy volunteers: 18FDG PET study. Psychiatry Research - Neuroimaging, 2009, 171, 199-206.	1.8	10
44	A common variant in DRD3 gene is associated with risperidone-induced extrapyramidal symptoms. Pharmacogenomics Journal, 2009, 9, 404-410.	2.0	50
45	Insertion/deletion polymorphism of the angiotensin-converting enzyme gene is associated with schizophrenia in a Spanish population. Psychiatry Research, 2009, 165, 175-180.	3.3	38
46	ARVCF single marker and haplotypic association with schizophrenia. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2009, 33, 1064-1069.	4.8	15
47	Progressive gray matter changes in first episode schizophrenia: A 4-year longitudinal magnetic resonance study using VBM. Schizophrenia Research, 2009, 114, 136-143.	2.0	94
48	Cannabis use and age of diagnosis of schizophrenia. European Psychiatry, 2009, 24, 282-286.	0.2	41
49	Treatment of Narcolepsy Complicated by Psychotic Symptoms. Psychosomatics, 2009, 50, 427-428.	2.5	9
50	CYP2D6*3, *4, *5 AND *6 POLYMORPHISMS AND ANTIPSYCHOTIC-INDUCED EXTRAPYRAMIDAL SIDE-EFFECTS IN PATIENTS RECEIVING ANTIPSYCHOTIC THERAPY. Clinical and Experimental Pharmacology and Physiology, 2008, 35, 807-811.	1.9	36
51	Glucose abnormalities in the siblings of people with schizophrenia. Schizophrenia Research, 2008, 103, 110-113.	2.0	84
52	Association of A/G Polymorphism in Intron 13 of the Monoamine Oxidase B Gene with Schizophrenia in a Spanish Population. Neuropsychobiology, 2008, 58, 65-70.	1.9	21
53	Pharmacokinetics and time-course of D2 receptor occupancy induced by atypical antipsychotics in stabilized schizophrenic patients. Journal of Psychopharmacology, 2008, 22, 882-894.	4.0	29
54	Fluordeoxyglucose-PET study in first-episode schizophrenic patients during the hallucinatory state, after remission and during linguisticâ€“auditory activation. Nuclear Medicine Communications, 2008, 29, 894-900.	1.1	29

#	Article	IF	Citations
55	Dopamine transporter (DAT) genotype (VNTR) and phenotype in extrapyramidal symptoms induced by antipsychotics. Schizophrenia Research, 2007, 90, 115-122.	2.0	45
56	Lower striatal dopamine transporter binding in neuroleptic-naive schizophrenic patients is not related to antipsychotic treatment but it suggests an illness trait. Psychopharmacology, 2007, 191, 805-811.	3.1	57
57	Long-acting injectable risperidone in the treatment of schizophrenia in special patient populations. Psychopharmacology Bulletin, 2007, 40, 82-100.	0.0	11
58	Clinical experience and management considerations with long-acting risperidone. Current Medical Research and Opinion, 2006, 22, 241-255.	1.9	27
59	Efficacy and safety of direct transition to risperidone long-acting injectable in patients treated with various antipsychotic therapies. International Clinical Psychopharmacology, 2005, 20, 121-130.	1.7	105
60	Decreased striatal dopamine transporter binding assessed with [123I] FP-CIT in first-episode schizophrenic patients with and without short-term antipsychotic-induced parkinsonism. Psychopharmacology, 2005, 181, 401-406.	3.1	40
61	Patients in the early phases of schizophrenia and schizoaffective disorders effectively treated with risperidone long-acting injectable. Journal of Psychopharmacology, 2005, 19, 5-14.	4.0	88
62	Lack of sex differences in striatal dopamine D2 receptor binding in drug-naive schizophrenic patients: an IBZM-SPECT study. Psychiatry Research - Neuroimaging, 2004, 130, 79-84.	1.8	21
63	Striatal dopamine D 2 receptor density in neuroleptic-naive and in neuroleptic-free schizophrenic patients: an 123 I-IBZM-SPECT study. Psychopharmacology, 2004, 172, 165-169.	3.1	18
64	Risperidone in the Treatment of Patients With Delirium. Journal of Clinical Psychiatry, 2004, 65, 348-353.	2.2	95
65	Double-blind olanzapine vs. haloperidol D2 dopamine receptor blockade in schizophrenic patients: a baseline-endpoint [123I]IBZM SPECT study. Psychiatry Research - Neuroimaging, 2001, 107, 87-97.	1.8	28
66	Manic Syndrome Associated with Efavirenz Overdose. Clinical Infectious Diseases, 2001, 33, 270-271.	5.8	57
67	Role of the cingulate gyrus during the Wisconsin Card Sorting Test: a single photon emission computed tomography study in normal volunteers. Psychiatry Research - Neuroimaging, 1998, 83, 67-74.	1.8	26
68	The resting and activation issue of hypofrontality: a single photon emission computed tomography study in neuroleptic-naive and neuroleptic-free schizophrenic female patients. Biological Psychiatry, 1998, 44, 787-790.	1.3	40
69	Regional cerebral blood flow pattern in normal young and aged volunteers: a99mTc-HMPAO SPET study. European Journal of Nuclear Medicine and Molecular Imaging, 1996, 23, 1329-1337.	2.1	81
70	Prefrontal dysfunction in young acute neuroleptic-naive schizophrenic patients: A resting and activation SPECT study. Psychiatry Research - Neuroimaging, 1994, 55, 131-139.	1.8	89
71	Hypophyseal response to ECT: A higher and faster vasopressin peak. Biological Psychiatry, 1993, 33, 670-672.	1.3	5